Status:
COMPLETED
Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy Subjects
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Study to examine the concentration of the study drug, tigecycline, in human bone samples following the administration of multiple doses.
Eligibility Criteria
Inclusion
- Inclusion:
- Men and nonlactating and nonpregnant women greater than or equal to 18 years of age.
- Healthy as determined by the investigator on the basis of medical history, physical examination, vital signs, and 12-lead electrocardiogram (ECG).
- Have a high probability for compliance with and completion of the study.
- Exclusion:
- Subjects with chronic osteomyelitis.
- Subjects who have known or suspected hypersensitivity to tigecycline or other tetracyclines.
- Involvement in other investigational studies of any type within 30 days before test article administration.
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00376324
Start Date
September 1 2006
End Date
October 1 2008
Last Update
July 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85006